The raging semiconductor rally received another boost this week when UBS analyst Timothy Arcuri raised his price target on Micron Technology Inc. (NASDAQ: MU) to a stunning $1625, nearly triple its previous target.
The stock was trading under $800 at the time of the upgrade, so the new target rep.... |
Good MorningThe tape leaned risk-on Thursday, with AI software pulling broader benchmarks to fresh records even as hot inflation and Iran tensions cut the other way. The central tension: AI earnings momentum versus a stagflation backdrop complicating the Fed picture. Mega-cap software stepped into the leadership role chips had been carrying alone.
April PCE climbed to a three-year high as the Iran war's oil shock fed through, a hawkish complication for new Fed Chair Kevin Warsh's rate path. Iran's strike on a U.S. air base and the ongoing Hormuz closure kept crude bid, though reports of a 60-day ceasefire extension capped the move. The mix favors quality earnings and pressures rate-sensitive corners.
Snowflake had its best day ever on a clean beat and rosy guidance tied to a $6 billion AWS Graviton deal, lifting Microsoft, Oracle, and Palantir on the AI-software trade. Salesforce slid on light fiscal 2027 guidance, fresh ammunition for AI-seat-pricing bears. NVIDIA and chip producers paused while analysts raised memory targets on Micron and SanDisk. Traders are watching Friday's Chicago PMI and consumer sentiment, Tehran's next move, and Fed speakers signaling whether the inflation print changes the rate-cut math.
Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
| Technology | |
The raging semiconductor rally received another boost this week when UBS analyst Timothy Arcuri raised his price target on Micron Technology Inc. (NASDAQ: MU) to a stunning $1625, nearly triple its previous target.
The stock was trading under $800 at the time of the upgrade, so the new target rep... Read the Full Story |
| From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7.
One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race. | | Get the name, ticker, and full Hotlist before markets open |
| Technology | |
Snowflake (NYSE: SNOW) is only the latest example of how the AI flywheel is gaining momentum. Demand for the company’s product is hot, exceeding expectations and driving management to increase spending. Increased spending leads to new demand, increased revenue, and an improved outlook—and the cycl... Read the Full Story |
| Technology | |
While retail capital chases the computational firepower of AI logic chips, a more fundamental story is unfolding in the circuitry that powers them. The insatiable energy demands of next-generation data centers and electric vehicles (EVs) are forcing a non-negotiable architectural shift from legacy ... Read the Full Story |
| From Our Partners | | A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | | Click here to learn this company's name for free today |
| Communication Services | |
In Q2, insiders are showing confidence in several key stocks across the entertainment, payments, and apparel industries. These names have experienced notable weakness in their share prices over the recent past. Amid this, insiders appear to see opportunity, buying more than $25 million worth of sh... Read the Full Story |
| Technology | |
As the artificial intelligence (AI) arms race hits a severe physical bottleneck, immediately available grid power has replaced raw silicon as the market's ultimate premium asset. The frantic demand for computing capacity has outstripped the electrical grid's ability to supply it, creating multi-yea... Read the Full Story |
| From Our Partners | | The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. | | See the 5 stocks to avoid |
| Technology | |
A profound disconnect is unfolding in the quantum computing space, centered on Rigetti Computing (NASDAQ: RGTI). While surface-level data points, like a mechanical shelf registration and routine insider selling, have triggered a retail-driven consolidation, a much more powerful fundamental and tech... Read the Full Story |
| Industrials | |
Modern warfare consumes munitions at a pace that has left the Western defense industrial base struggling to keep up. At the center of this challenge is a critical production bottleneck: the slow, inflexible, and costly manufacturing of traditional, single-use solid rocket motors (SRMs).
RTX Corp. ... Read the Full Story |
| Technology | |
Microsoft Corp. (NASDAQ: MSFT) delivered what, by almost any conventional measure, was a spectacular quarter.
Revenue climbed, cloud growth re-accelerated, and Azure posted numbers that beat even the most optimistic analyst models.
On paper, this is a company firing on every cylinder. And yet MSF... Read the Full Story |
| Healthcare | |
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bundibugyo virus Ebola outbreak should be seen by investors as more than a headline, because it is a f... Read the Full Story |
| Markets | |
After losing nearly 8% through the first three months of the year, the S&P 500 Index has rallied on a renewed AI trade and increasingly bullish investor sentiment. Large- and mega-cap U.S. equities have seen a surge in inflows, helping push the benchmark index up more than 18% since the start ... Read the Full Story |
| Friday's Early Bird Stock Of The Day Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. | Should I Buy Eli Lilly and Company Stock? LLY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Tuesday, August 25, 2026 at 6:03 PM.
Eli Lilly and Company Bull Case -
The company recently reported earnings per share significantly above analysts' expectations, indicating strong financial performance and potential for continued growth.
-
Eli Lilly and Co's revenue has shown impressive year-over-year growth, suggesting robust demand for its products and effective market strategies.
-
The current stock price is around $1,292, reflecting positive market sentiment and strong analyst ratings, with many recommending a buy.
-
The company has a high return on equity, which indicates efficient management and the ability to generate profits from shareholders' investments.
-
Eli Lilly and Co has a solid dividend payout ratio, providing investors with a reliable income stream through dividends, which can be attractive in a volatile market.
Eli Lilly and Company Bear Case -
Despite strong earnings, the pharmaceutical industry is highly competitive, and Eli Lilly and Co may face challenges from new entrants and existing competitors.
-
The company's dividend yield is relatively low, which may not appeal to income-focused investors looking for higher returns from dividends.
-
Market volatility can impact stock prices, and any negative news regarding the company or the industry could lead to significant price fluctuations.
-
Regulatory changes in the pharmaceutical sector can pose risks to profitability and operational stability, affecting investor confidence.
-
While the company has strong growth potential, it also carries risks associated with research and development, including the possibility of unsuccessful product launches.
| | View Today's Stock Pick |
|
| |
|
|
